Trials / Completed
CompletedNCT00039858
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Encysive Pharmaceuticals · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Argatroban |
Timeline
- Start date
- 2003-09-01
- Completion
- 2006-03-01
- First posted
- 2002-06-14
- Last updated
- 2007-01-11
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00039858. Inclusion in this directory is not an endorsement.